The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial
Table 1
Baseline characteristics.
Everolimus ()
CNI ()
value
Age (years), mean ± SD
0.46
Female, (%)
2 (6.9)
1 (3.6)
1.0
Ethnic origin, Caucasian, (%)
29 (100)
28 (100)
1.0
Time posttransplant (years), median; IQR
7.6; 4.1–12.9
6.5; 3.7–12.1
0.82
Medical history, (%)
Hypertension
24 (82.8)
27 (96.4)
0.19
Diabetes mellitus
7 (24.1)
3 (10.7)
0.30
Laboratory values, mean ± SD
mGFR (mL/m)
0.38
Creatinine (mg/dL)
0.19
eGFR (mL/min/1.73 m2)
0.09
Urea (mg/dL)
0.28
Total cholesterol (mg/dL)
0.95
Proteinuria (g/L)
0.20
Immunosuppression, (%)
Cyclosporine
19 (65.5)
20 (71.4)
0.63
Tacrolimus
10 (34.5)
8 (28.6)
0.63
MMF
29 (100)
28 (100)
1.0
Methylprednisolone
15 (51.7)
13 (46.4)
0.69
Concomitant medication, (%)
ACE-inhibitors
13 (44.8)
18 (64.3)
0.14
ARB
4 (13.8)
4 (14.3)
1.0
Loop diuretics
13 (44.8)
3 (10.7)
0.004
Spironolactone
3 (10.3)
0
0.24
Statins
29 (100)
28 (100)
1.0
SD, standard deviation; MMF, mycophenolate mofetil; ARB, angiotensin receptor blocker.
